Press Release

November 3, 2026 BSE Limited The National Stock Exchange of India Ltd Phiroze Jeejeebhoy Towers, Exchange Plaza, 25th Floor, Dalal Street, Bandra Kurla Complex Mumbai – 400 001 Bandra (E), Mumbai – 400 001 Scrip Code: 524558 Scrip Code: NEULANDLAB; Series: EQ Dear Sir/Madam, Sub: Press Release Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing Press Release on the Financial Results of the Company for the quarter and half year ended September 30, 2026. The Press Release is also being uploaded on the website of the Company at www.neulandlabs.com This is for your information and records. Yours sincerely, For Neuland Laboratories Limited Sarada Bhamidipati Company Secretary Encl: As above Press Release Q2 FY27 | Standalone Results Neuland Laboratories Reports Q2 FY27 Standalone Revenue of ₹457.2 Cr EBITDA at ₹104.6 Cr, EBITDA Margin at 22.9% Hyderabad, India, November 3, 2026: Neuland Laboratories Limited (“Neuland” or “the Company”) (NSE: NEULANDLAB; BSE: 524558), a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions (CMS) to customers in around 80 countries, today announced its unaudited Standalone Financial Results for the quarter and half year ended September 30, 2026, as approved by its Board of Directors. Q2FY27 and H1FY27 Financial Summary (₹ in Crores, except EPS and percentages) Particulars (₹ Cr, Q2 FY 27 Q2 FY 26 YoY% Q1 FY 27 QoQ% H1 FY 27 H1 FY 26 YoY% unless stated) Total Income 457.2 516.1 -11.4% 650.1 -29.7% 1,107.2 816.7 35.6% EBITDA 104.6 156.9 -33.4% 231.1 -54.8% 335.6 199.1 68.6% EBITDA Margin 22.9% 30.4% -754 BPS 35.5% -1267 BPS 30.3% 24.4% 594 BPS Profit Before Tax 68.5 129.0 -46.9% 197.5 -65.3% 266.0 146.4 81.7% PBT Margin 15.0% 25.0% -1002 BPS 30.4% -1541 BPS 24.0% 17.9% 610 BPS Profit After Tax 51.1 96.5 -47.0% 147.4 -65.3% 198.5 110.2 80.2% PAT Margin 11.2% 18.7% -751 BPS 22.7% -1148 BPS 17.9% 13.5% 444 BPS EPS (₹, Diluted) 39.9 75.2 -47.0% 114.9 -65.3% 154.7 85.9 80.2% Key Financial Highlights ● Standalone revenue decreased 11.4% YoY to ₹457.2 Cr; commercial CMS projects contributed the majority share of revenue. ● EBITDA for the quarter stood at ₹104.6 Cr, with EBITDA margin reducing to 22.9% (down 754 bps YoY) due to operating deleverage. ● Profit After Tax for the quarter stood at ₹51.1 Cr, down from ₹96.5 Cr in Q2FY26, with PAT margin at 11.2% (down 751 bps YoY). ● Diluted EPS for the quarter was ₹39.9, compared to ₹75.2 in Q2FY26. Working capital efficiency improved meaningfully, with working capital days reducing to 104 days in H1FY27 from 155 days at H1FY26, driven largely by decrease in inventory days and receivable days. ● Capex investment cash outflow of Rs. 261 Cr is largely driven by New R&D and Peptide Block. Business Highlights ● Inauguration of the new peptide manufacturing facility, with encouraging visibility supported by a growing pipeline of upcoming projects. ● Acquisition of approximately 134 acres of land in Kakinada, AP, providing a strategic base to support Neuland’s long-term capacity and growth requirements. ● 2 DMFs filed in Q2FY27 for Fezolinetant and Ivacaftor. Management Commentary Commenting on the performance, Mr. Saharsh Davuluri, Chief Executive Officer and Managing Director, Neuland Laboratories, said: “While we have experienced a dip in performance this quarter, H1 FY27 was largely in line with plan and our growth expectations remain intact for FY27 and the following year. Commercial CMS molecules continue to drive near-term growth, while strong RFP activity along with progress on traction with Big Pharma support customer diversification and the longer-term pipeline. The investments in peptides, R&D and land acquisition strengthen our capabilities while enabling us to expand with agility.” Q2FY27 Earnings Call The Company will host a one-hour earnings call on Tuesday, November 3, 2026, at 17:30 hrs. IST, during which management will discuss the Company's performance and respond to questions from participants. Participants may join using the Diamond Pass registration link or the webcast link below: Date Tuesday, November 3, 2026 Time 17:30 hrs. IST (one hour) Webcast Webcast Link Transcript To be made available on the Company's website in due course About Neuland Laboratories Limited For over four decades, Neuland Laboratories has been at the forefront of manufacturing active pharmaceutical ingredients (APIs) through its cGMP manufacturing facilities, working with customers in close to 80 countries. Neuland has developed more than 300 processes and 100 APIs and has filed over 1,016+ regulatory filings across the US (77 active US DMFs), the European Union and other geographies. Its record of quality manufacturing and reliability is underpinned by cGMP certifications, including from the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), CFDA (China), FSI “SID & GP” (Russia) and Health Canada, along with ISO 9001, ISO 14001, OHSAS 18001 and ISO 27001 certifications. For more information, visit www.neulandlabs.com. Forward-Looking Statements This press release may contain forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects on the Company. These statements involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied. Factors that could cause such differences include, among others, general economic and business conditions in India, the Company's ability to successfully implement its strategy, its research and development efforts, growth and expansion plans, technological changes, and changes in applicable laws and regulations. Neuland Laboratories undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. For further information, please contact: IR Department, Neuland Laboratories Email: ir@neulandlabs.com Tel: +91 40 6761 1600 EY IR Runjhun Jain / Minakshi Machutre Email: Runjhun.Jain1@in.ey.com / Minakshi.machutre@in.ey.com